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Sumnmay- Epidermal growth factor receptor (EGFR) has been the subject of much research since it was first
described as a prognostic factor in breast cancer. The assay methods used and results obtained vary widely
between studies. In this study 88 primary breast cancers were assayed for EGFR using a novel immunohis-
tochermcal assay performed on paraffin-embedded sections. The monoclonal antibody used was raised against
purified, denatured EGFR, reacts with an epitope on the external domain and does not interfere with ligand
binding. Twenty-two per cent of the tumours were EGFR positive using this assay. The results obtained were
significantly correlated with those obtained by ligand-binding assay (r= 0.621. P= 0.011). The concordance
rate was 82%(P<0.0001). The majority of discordant results could be explained by the presence of benign
breast tissue and other non-malignant elements which could be seen to express EGFR on the immunohis-
tochemical assay and were excluded from the score for this, but would be incorporated into ligand-binding
assay results. The well-established inverse relationship between EGFR (as measured by this assay) and
oestrogen receptor (ER) was seen (Q=24.9. P<0.0001). In addition, in this exploratory study on a limited
tumour set. EGFR was a significant adverse prognostic factor (on umnvariate but not multivariate analysis) for
both relapse-free survival (P=0.02) and overall survival (P=0.03) when measured by this immunohisto-
chemical assay. but was not significant when measured by ligand-binding assay.
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EGFR is a 170 kDa cell-surface receptor with an external
domain containing the ligand-binding region, a short trans-
membrane domain and an intracellular domain containing a
region with tyrosine kinase activity. It is one of an expanding
group of homologous transmembrane receptors with tyrosine
kinase activity which currently comprises EGFR, c-erb B-2,
c-erb B-3 and recently c-erb BA4 (Carraway and Cantley,
1994; Rajkumar and Gullick, 1994). EGFR has a number of
ligands, including epidermal growth factor (EGF), transform-
ing growth factor alpha, amphiregulin, cripto and heparin-
binding EGF. EGFR is present on a number of benign and
malignant human cell lines, including some human breast
cancer cell lines. In vitro, EGFR and its ligands have been
implicated in malignant transformation via autocrne and
paracrine growth factor pathways (Normanno et al., 1994).
In vivo, EGFR is expressed in a number of human tissues,
both normal and malignant. Among cancers, EGFR is most
strongly expressed in squamous cell carcinomas, but it is also
found in a variety of other tumours, including approximately
45% of breast adenocarcinomas (Klijn et al., 1992). A
number of studies have shown it to be an adverse prognostic
factor in breast cancer (Sainsbury et al., 1987; Costa et al.,
1988; Harris et al., 1989; Lewis et al., 1990; Spyratos et al.,
1990; Nicholson et al., 1991; Toi et al., 1991; Gasparini et al.,
1992; Koenders et al., 1993; Fox et al., 1994), though this is
not confirmed in all such studies (Foekens et al., 1989;
Coombes et al., 1990; Murray et al., 1993; reviewed in Klijn
et al., 1992; Fox et al., 1994). In contrast, the literature is
consistent in reporting an inverse relationship between
EGFR and ER (reviewed in Klijn et al., 1992). EGFR has
also been shown to be an indicator of a poor chance of
response to endocrine therapy (Nicholson et al., 1988a; Har-
ris et al., 1989; Nicholson et al., 1994).
A number of assays have been used to measure EGFR, of
which the most widely applied is the ligand-binding assay
(LBA) (Nicholson et al., 1988b). This method requires a
relatively large amount of fresh-frozen tissue, is cumbersome
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to perform and cannot be applied to archival material. Other
methods have been used, such as enzyme immunoassay (EIA)
Iwase et al., 1993) (which also requires frozen tissue),
immunohistochemistry (predominantly on frozen sections)
(Parker et al., 1984), mRNA detection methods (Coombes et
at., 1990), autoradiography (Reubi and Torhorst. 1989) and
EGFR-associated phosphotyrosine kinase activity (Baugnet-
Mahieu and Lemaire, 1990).
Ligand-binding assay is generally accepted as the 'gold
standard' in EGFR measurements, though even here there is
disagreement about the cut-off used to define positivity (Klijn
et al., 1992). Immunohistochemical assays (IHAs) are simple
to perform, can be semiquantitative and have the advantage
over LBA of showing the tissue distnrbution of EGFR. How-
ever, there are two major problems with the IHAs descnrbed
in the literature. Firstly, the majonrty do not work on
paraffin-embedded material and so cannot be applied to
archival material. Secondly, few studies have attempted to
validate the assays used. In addition some anti-EGFR
antibodies are raised against receptor in glycosylated form.
These will potentially cross-react with blood group antigens
and make interpretation of results difficult (Gerdin et al..
1992). Care must therefore be taken to ensure that the
antibody used (in any assay method) is raised against
epitopes on the EGFR protein and not on associated car-
bohydrate moieties.
We have developed an immunohistochemical assay for
EGFR which works on paraffin-embedded sections and have
validated this on a tumour set for which EGFR had
previously been measured by ligand-binding assay. To find a
clinically relevant cut-off point for this assay, analysis of the
prognostic significance was deterniined for all possible values.
The expected relationship with ER status was also assessed.
-Materials and metbods
Patient selection
Eighty-eight cases of previously untreated primary operable
breast cancer were selected from the database at the JohnXIM. chemical assay for EGFR
JC Newby eta
1238
Radcliffe Hospital from 1989 to 1991. The criteria for selec-
tion were that EGFR had been previously measured by
ligand-binding assay (Nicholson et al.. 1988b) and that oest-
rogen receptor (ER) status was known. Five micron paraffin
sections from a representative block of each case were used
for immunostaining.
Information on patient age. tumour size, adjuvant therapy
and clinical course was taken from the breast cancer patient
database. The median age of these patients was 55 years
(range 28-83 years). Tumours ranged in size from 1.0 to
8.0 cm (mean 2.5 cm). In six cases nodal status was not
known. Of the remaining 82, 43 were node positive (52%).
Sixty per cent of cases were ER positive (> 5 fmolmg-'
protein). Of the 88 patients, 26 received no adjuvant systemic
therapy, 23 received chemotherapy alone, 35 received hor-
mone therapy alone (33 tamoxifen, two aminoglutethimide),
two received both and for two this information was not
available. Follow-up was at 3 month intervals, with a median
length of 39 months (range 17-51 months).
EGFR immunohistochemical assay
The antibody used in this assay was a mouse monoclonal,
subclass IgGl. raised against purified, denatured EGFR, and
kindly provided by Biogenex, CA. USA (Cat. No. MU-207-
UC). It reacts with a polypeptide epitope of the external
domain of the molecule and does not interfere with EGF
binding. A series of preliminary experiments were conducted
to optimise the staining procedure. The final conditions
selected were as follows: tissue was routinely fixed in for-
malin and then embedded in paraffin wax blocks. Five mic-
ron sections from the blocks were dewaxed in xylene, then
hydrated through graded alcohols to water. After washing in
water, endogenous peroxidase activity was blocked using a
3% solution of hydrogen peroxide in distilled water for
15 mmn at room temperature. Slides were washed then taken
to phosphate-buffered saline (PBS) at 37C for 15 min, fol-
lowed by digestion in pronase (Sigma) at 0.05% (w/v) in PBS
for 15 mmn at 37C. After washing in PBS. non-specific bin-
ding was blocked using normal rabbit serum (Dako) diluted
1:5 in PBS. This was drained, primary antibody (MU207)
applied at a dilution of 1:10 in PBS and the slides were then
incubated at room temperature overnight. Following washing
in PBS, secondary antibody (biotinylated rabbit anti-mouse
IgG; Dako) was added and incubated for 1 h at room
temperature. Slides were washed again and strep-
tavidin-biotin-horseradish peroxidase complex (Dako) app-
lied and incubated for 30 mm at room temperature. Slides
were washed again and developed in 0.05% 3.3'-
diaminobenzidine solution with hydrogen peroxide. Sections
were counterstained with Mayer's haematoxylin. Control
slides of known EGFR-positive and -negative breast cancers
were included in each staining run.
Slides were scored for percentage malignant cells showing
membrane staining, averaged across ten high-power fields.
and for overall intensity of staining on a scale of 0-3 (0
being no staining. I weak staining. 2 moderate staining and 3
strongly positive staining). The two scores were then multip-
lied to give the final result (possible range 0-300). A score of
) 35 was counted as positive (see Results). The staining and
scoring for EGFR were performed without knowledge of any
other data [e.g. ER. EGFR (LBA), clinical outcome]. The
prelminary assay optimisation experiments indicated that
although staining for EGFR was heterogeneous within any
one section. scores obtained by this method were similar for
different sections of a tumour, and even for initial diagnostic
biopsy and surgical excision specimens from the same
patient.
EGFR ligand-binding assay
This was performed as previously described (Nicholson et al..
1988b). Results are expressed as fmol mg-' protein: a value
of )20 fmol mg- ' protein is the cut-off used for this assay in
routine practice in Oxford.
ER assay
This was measured by the dextran-coated charcoal method
(EORTC. 1980). Tumours with )5 fmol mg- ' cytosolic pro-
tein were considered positive.
Results
EGFR immunostaining
The pattern of staining in these cases largely conformed to
known EGFR distribution. In normal tissues within the sec-
tions. skin epithelial cells were positive. with the strongest
staining being in the basal layer cells. In benign breast tis-
sues, both luminal and myoepithelial cells stained, with
myoepithelial cells generally stronger. Stromal fibroblasts
were weakly positive in some areas. both normal and malig-
nant. Inflammatory cells were negative. with the exception of
occasional plasma cells. in which intense cytoplasmic staining
was seen. and some foamy macrophages in areas of duct
ectasia which showed weak membrane staining. Smooth mus-
cle in blood vessel walls stained. as did nerve sheath cells.
Within the breast cancers, when positive. malignant
epithelial cells showed clear membrane staining (Figure 1).
This membrane staining was generally heterogenous through-
out the tumour. In addition. in a small number of cases there
were some linear streaks of positive staining in the stroma
surrounding nests of tumour cells. This was interpreted as
representing remnants of normal tissue disrupted by malig-
nant expansion. Only cases in which clear membrane staining
of malignant epithelial cells was seen were counted as
positive and scored. In a number of cases foci of benign
breast epithelium staining positively for EGFR were found
within tumours which were negative for EGFR (Figure 2).
Definition ofpositivitYfor EGFR
A discriminatory value for EGFR(IHA) positivity was
optimised by continuous testing across the range of all possi-
ble values in relation to prognosis (relapse-free and overall
survival). The value selected was that which was associated
with the greatest statistical significance for the comparison
between the two groups it defined. For EGFR(IHA) this
gave an optimal cut-off of 35. with 22% of the cases defined
as positive. This compared with 44% of cases positive for
EGFR(LBA) using the conventional cut-off of >20
fmol mg-' protein.
Optimising the cut-off for the EGFR(LBA) data gave a
cut-off value of approximately 80 fmol mg-'. defining only
12% of cases as positive. This was too small a group on
which to perform meaningful survival analysis. To allow a
valid comparison between the prognostic significance of the
two methods, an alternative approach was taken: a cut-off
for EGFR(LBA) which defined the same proportion (22%)
of cases as positive as the optimised EGFR(IHA) was found.
This gave a cut-off of 38 fmol mg-'.
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Figure 1 Breast carcinoma showing strongly positive staining for
EGFR (IHA score = 300). Bar =50pm.I _mnwnoiskacen*aM assayfor EGFR
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The different cut-offs are referred to below as EGFR(LBA-
20) and EGFR(LBA-38). For all analyses the optimised cut-
off of 35 is used for EGFR(IHA).
Correlation with ligand-binding assai results
Of the 19 88 (22%) cases which showed positive immunos-
taining of malignant epithelial cells. 14/19 (74%) were also
positive on ligand-binding assay (LBA-20). Of those negative
on immunostaining. 44/69 (64%) were also negative on
ligand-binding assay. Overall there was agreement between
EGFR as assessed by immunostaining (EGFR-IHA) and on
ligand-binding assay (EGFR-LBA-20) in 66% of cases
(P = 0.004). On a simple linear regression plot (Figure 3), it
can be seen that the majority of the cases with discordant
results were negative on immunostaining but positive to a
variable degree on LBA. It is probably significant that, of the
25 cases which were negative for EGFR (IHA) but positive
for EGFR(LBA-20). 16 sections also contained some benign
breast epithelium, and in 14 of these 16 cases the benign
epithelial elements were positive for EGFR. The intensity of
staining in benign breast epithelium was similar to that seen
in malignant epithelium. When the optimised LBA cut-off
(LBA-38) was applied, the concordance increased to 82%
(P<0.0001). It can be seen from Figure 3 that the improved
concordance using EGFR (LBA-38) is largely due to the loss
from the relationship of cases which were IHA negative but
LBA-20 positive.
Association with other parameters
No association was found between EGFR measured by
either method and patient age or tumour size. Table I shows
the number of EGFR-positive cases divided according to
number of nodes involved for both assay methods. The
expected inverse relationship with ER exists for EGFR as
measured by IHA (X: = 24.9, P<0.0001) and for
EGFR(LBA-38)(j = 8.3, P = 0.0071), though it is not
significant for EGFR (LBA-20) (Table I). Only two tumours
were positive for both EGFR (IHA) and ER.
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Fwe 3 Linear correlation between EGFR(IHA) and
EGFR(LBA) [cut-offs marked: ----, EGFR(IHA);
= EGFR(LBA-20); = EGFR(LBA-38)].
Prognostic value
Table II shows the results of univanrate analysis of prognostic
factors for this set of patients. It can be seen that, while
nodal status was the most powerful prognostic factor of
those analysed, size 2.5 cm (P = 0.01), ER status
(P = 0.05) and EGFR (IHA) (P = 0.02) were all significant
Table I Relationship between ER and EGFR
EGFR(IHA) EGFR(LBA-20J EGFR(LBA-38}
ER -ve + ve -ve + ve -ve + ve
-ve 18 17 15 20 22 13
+ve 51 2 34 19 47 6
= 24.9. P<0.000I Not significant = 8.3, P= 0.0071
Table 11 Univariate analysis of prognostic factors for relapse-free (RFS) and overall (OS)
survival
RFS OS
Hazard ratio p-value Hazard ratio p-value
EGFR(IHA) 2.38 (1.11-5.12)r 0.02 2.60 (1.09-6.22) 0.03
EGFR(LBA-20) 1.15 (0.56-2.35) NS 1.09 (0.47-2.53) NS
EGFR(LBA-38) 1.82 (0.83-3.99) NS 2.13 (0.87-5.24) NS
Age ( > 55 years) 1.22 (0.60-2.50) NS 1.35 (0.58-3.12) NS
Size ( >2.5 cm) 2.51 (1.17-5.37) 0.01 1.41 (0.58-3.39) NS
ER 0.49 (0.24-1.00) 0.05 0.77 (0.33-1.79) NS
No. of nodes
0 1.00 1.00
1 -3 2.39 (1.47-3.87) <0.001 3.35 (1.83-6.13) <0.001
>4 5.70 (3.52-9.24) 11.21 (6.12-20.53)
aFigures in brackets = 95% confidence intervals. NS, not significant.
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Fugwe 4 Survival curves for reLpse-free (a) and overall survival
(b) stratified by EGFR(1HA). , EGFR<35; -- -
EGFR > 35.
for relapse-free survival (RFS), and EGFR (IRA) (P= 0.03)
was the only other significnt factor for overall survival (OS).
EGFR (LBA-20 or -38) was not significant either category.
Figure 4 shows the survival curves for RFS and OS stratified
by EGFR(IHA) (log-rank test and Kaplan-Meier product-
lmit method). Of the 88 patients, 23 had died during the
follow-up period (15 node positive); ten had suffered recur-
rence but were still alive (seven node positive) and 55
remained disease free.
In multivariate anysis, using the Cox rLegresson model
and including all of the factors significant in univariate
analysis, nodal status (P<0.001) and ER status (P<0.01)
were independent factors for RFS; only nodal status was an
independent prognostic factor for OS (P<0.001).
Discesdon
Since Sainsbury et al., first described EGFR as a prognostic
factor in human breast cancer in 1985 (using a ligand-binding
assay method), there have been a large number of studies
which have measured EGFR in breast cancers by a variety of
methods and with differing definitions and thus proportions
of positivity. Grimaux et al. (1989) did not find EGFR
(measured by LBA) to be of prognostic signince in a
group of 68 node-positive cases but used a cut-off of 5
fmol mg' protein rather than 10 fmol mg-', which was more
widely used. Using 10 finol mg-' as a cut-off, Spyratos et al.
(1990) again did not find EGFR to have prognostic
significnce in either node-positive or node-negative patients.
Other studies have agreed with Sainsbury's findings (e.g.
Costa et al., 1988, using LBA and Lewis et al., 1990, using
IHA on frozen sections).
Ligand-binding assay is the most widely applied method
and is the current 'gold standard' for measuring EGFR.
Immunohistochemical assays have the general advantages of
being quick and simple to perform, requiring little material
and showing the tissue distribution of the antigen concerned.
Some studies have compared the results of LBA and IHA
assays for EGFR In their orginal study, Sainsbury et al.
(1985) found that results obtained by immunostaining with
the EGFR-1 antibody on frozen sections 'correlated with' the
results of ligand-binding assay. In a more formal com-
parison, Toi et al. (1989) found a 94% concordance between
immunotaining with the EGFR-1 antibody and results of
ligand-binding assay. Using the same antibody in ovarian
carcnomas, a concordance of 67% was found between the
two methods (Owens et al., 1992). Using a different antibody,
MAb 425, on breast cancers, no signint differences wer
seen when EGFR which had been measured both
biochemically and immunohistochemialy was indeently
correlated with other tumour characteristis, but this study
did not directly compare the two assay results (Becinman et
al., 1993). All of the above immunohistochemical studies
were performed on frozen sections. A recent study has com-
pared LBA, EIA and IHA and found reasonable agreement
between the results of the three methods (72% concordance
between IHA and LBA) (Iwase et al., 1993). That study
concluded that EIA is the most appropriate method for use
with clinical samples on the basis that it had the strongest
prognostic value in the patient group examined. None of the
IHAs described in these studies were conducted on paraffin-
embedded sections, a procedure which has been difficult to
perform successfully for EGFR. The availability of such an
assay would be extremely valuable in the investigation of the
biological/clical signifia of EGFR in the enormous
stores of archival pathological material.
We have descibed and validated an immunohistochemical
assay for EGFR which works on formalin-fixed, paraffin
wax-embedded sections. This employs a monoclonal antibody
whch is raised against purified EGFR and does not cross-
react with blood group antigens. This cross-reaction has been
shown to be a problem with some previously described
immunohistochemical assays for EGFR (Gerdin et al., 1992).
The pattern of staining produced by this assay is consistent
with the known distribution of EGFR in breast tissues, both
benign and malignant, and also in other normal components
of these sections such as skin, nerves and smooth muscle
(Damjanov et al., 1986). It has the significant advantage over
LBA/EIA of showing the tissue distribution of the EGFR,
eliminating the problem of possible confounding of results by
expression in normal breast epithelium (and other tissue
elments). Benign breast epithelium has been previously
shown to express higher mean levels of EGFR than malig-
nant breast epithelium by both LBA and immunohis-
tochemistry on frozen material (Travers et al., 1988; Barker
et al., 1989; Dittadi et al., 1993).
The proportion of tumours staining positively by this IHA
is relatively low (22%). This is at the lower end of the range
of positivity rates found in other studies (14-91% for a
variety of assay methods, 14-65% for immunohistochemical
analyses using the EGFR1 antibody on frozen tissue; Klijn et
al., 1992). Our positivity rate may be within the expected
variability range found when comparing results across several
often relatively small studies. Alternatively, it may relate to
the assay method in which antigen retrieval in the form of
protease digestion is essential. The length of the digestion
phase of the protocol is limited by the need to preserve tissue
morphology. It is possible therefore that the sensitivity ofthe
assay is reduced relative to other methods as one may be
unable to 'retrieve' all antigen present while still preserving
tissue morphology.
Measurement of EGFR using this immunohistochemical
assay shows a positive, but by no means perfect, correlation
with the ligand-binding assay, and as described above there
are good reasons for arguing that LBA, or any of the other
methods which use homogenates of tissue, are not the most
appropriate methods for assessng EGFR in clinical material.
The majority of discordant results are those which are
negative by immunotaining but positive by LBA. The
majority of these have positive-staining benign breast
epithelium. While these paraffin sections are not contiguous
with the portions oftumour used in the LBA, it does provideImnohmuohemical assay for EGR
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a probable explanation for the majority of discordant results.
This immunohistochemical assay may therefore be more ap-
propriate for use with clinical specimens.
The numbers of patients investigated is too small for a
formal study of prognosis, and the optimisation ofcut-off for
the IHA not only inevitably led to it having prognostic
significance, but also has statistical problems (Altman et al..
1994). All the same, it was felt that the potential clinical
usefulness of this approach to EGFR measurement could be
preliminarily assessed by comparing its prognostic
significance and relationship with other tumour parameters in
this group of patients with those of the ligand-binding assay
results. The intention was to compare the value of an estab-
lished method with a new method in this cohort of limited
size. When compared with the LBA, EGFR (IHA) showed
the expected inverse association with ER while EGFR (LBA-
20) did not (Table I). EGFR (LBA-38) did show a significant
inverse correlation, but the relationship was not as strong as
that with the IHA ( = 8.3 vs = 24.9). No association was
seen between nodal status and EGFR measured by either
method. In terms of prognosis, (Table II) EGFR (IHA) was
a significant factor (on univariate analysis) for both RFS and
OS and retained significance on multivariate analysis for
RFS (P<0.01). EGFR (LBA-20 or -38) was not a significant
prognostic factor for either RFS or OS.
The data on comparability are thus very encouraging,
indicating that the IHA is likely to be at least as useful as the
LBA for clinical assessment of EGFR. The statistically
stronger relationships with EGFR(IHA) may be due to the
exclusion by this approach of EGFR-expressing normal
benign tissue, which would be expected to be biologically less
relevant (or entirely irrelevant) in relation to disease progres-
sion. Confirmation of the prognostic significance of
EGFR(IHA) would obviously require a much larger patient
group. Such a study is planned for the near future.
In conclusion, we have developed and validated an
immunohistochemical assay for EGFR which is quick and
simple to perform, requires small amounts of tissue and can
be applied to paraffin-embedded sections and thus to archival
matenal.
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